In the cytosol of lipogenic tissue, ketone bodies are activated by AACS (acetoacetyl-CoA synthetase) and incorporated into cholesterol and fatty acids. AACS gene expression is particularly abundant in white adipose tissue, as it is induced during adipocyte differentiation. In order to elucidate the mechanism controlling the gene expression of human AACS and to clarify its physiological role, we isolated the human promoter, characterized the elements required to initiate transcription and analysed the expression of the gene in response to PPARγ (peroxisome-proliferator-activated receptor γ ), an inducer of adipogenesis. We show that the human AACS promoter is a PPARγ target gene and that this nuclear receptor is recruited to the AACS promoter by direct interaction with Sp1 (stimulating protein-1).
INTRODUCTION
AACS (acetoacetyl-CoA synthetase, also known as acetoacetateCoA ligase; EC 6.2.1.16) is a cytosolic ketone body (acetoacetate)-specific ligase found in several lipogenic tissues [1] . It might play an important role in the provision of acetylCoA for lipogenesis [2] ; transfer of acetyl as acetoacetate, from the mitochondria to the cytosol, would operate in parallel with transfer via citrate and ATP-citrate lyase [3] .
AACS activity is highly regulated. It exhibits a 10-fold diurnal variation in liver of adult rats [4] and varies in parallel with changes in liver lipogenesis during development and starvation [2, 4] . Its activity is regulated by modulators that affect the activity of 3-hydroxy-3-methylglutaryl-CoA reductase and/or cholesterol biosynthesis in the liver and adrenals of adult rats. Thus AACS activity was depressed by feeding cholesterol or by mevalonate administration and was enhanced by the addition to the diet of mevinolin and/or cholestyramine [5] . Furthermore, the activity of AACS was substantially decreased in rat hepatocytes treated with 25-hydroxycholesterol [6] . The expression of the AACS gene is transcriptionally regulated by SREBP (sterol-regulatoryelement-binding protein), as deduced from a global analysis of gene expression by oligonucleotide arrays hybridized with RNA from livers of three lines of mice: mice overexpressing SREBP1a or SREBP-2, and SCAP (SREBP-cleavage-activating protein)-knockout mice [7] . In addition it has been shown that the activity of cytosolic AACS was decreased in livers from streptozotocininduced diabetic rats [8, 9] . Lowering AACS activity by 80 % partially inhibited glucose-induced insulin release, indicating that formation of short-chain acyl-CoA from acetoacetate in the cytosol is important for insulin secretion [10] .
The tissue-specific expression pattern of the AACS gene is precisely controlled. Human AACS mRNA is abundant in the kidney, heart and brain, but low in liver [11] . In rat, the AACS mRNA is particularly abundant in male subcutaneous white adipose tissue after weaning. In this tissue, AACS mRNA was preferentially detected in mature adipocytes, but not in preadipocytes, and increased during adipocyte differentiation [12] . The mouse gene is also expressed in adipose tissue, and GC box and C/EBPα (CCAAT/enhancer-binding protein α) motifs seem to be crucial for AACS promoter activity in the mouse adipocyte cell line, 3T3-L1 [13] . These results indicate that AACS contributes to the utilization of ketone bodies in fatty acidsynthesis during adipose tissue development.
To elucidate the mechanism controlling the gene expression of human AACS and to clarify its physiological role, we isolated the human promoter, characterized the elements required to initiate transcription and analysed the expression of the gene in response to PPARγ (peroxisome-proliferator activated receptor γ ) a known master regulator of adipogenesis. We show that the human AACS promoter is a TATA-less promoter with an Inr (initiator) sequence and several GC boxes that determined both its basal and PPARγ -stimulated activity. The binding of Sp1 (stimulating protein-1) to the GC boxes was confirmed in vivo by ChIP (chromatin immunoprecipitation) and in vitro by DAPA (DNA-affinity precipitation assay) experiments. We also showed that PPARγ transcriptionally induces the expression of the AACS gene by a non-canonical mechanism, as it is recruited to the AACS promoter by direct interaction with Sp1.
were from Sigma-Aldrich. Rosiglitazone was from Alexis Biochemical.
Plasmids constructs
Reporter plasmids are named by designating the 5 -ends of the AACS DNA fragment relative to the transcription start site. The human AACS promoter region, spanning − 1425 to + 79 bp, was amplified by PCR using the oligonucleotides AACSF (5 -gagctcGAGATCAGGGAGGCTCTGG-3 , positions − 1425 to − 1407) and AACSR (5 -aagcttACCTGGGACCGGAGGAAG-3 , positions + 62 to + 79); nucleotides in lower-case were added to provide SacI and HindIII sites at the 5 -and 3 -ends respectively. The PCR product was cloned into the p-GEM-T vector and subsequently subcloned into the SacI/HindIII restriction sites of the pGL3 basic luciferase reporter (Promega). Deletions in the 5 -flanking regions of the AACS promoter were constructed by PCR. The PCR used the following forward primers: p-97 (5 -gagctcGGGAGGGCGGGGCCTGGAAG-3 , positions − 97 to − 77); p-79 (5 -gagctcAAGGGGGCGGGGATTCGAG-3 , positions − 79 to − 61); p-66 (5 -gagctcTTCGAGGCGGGGCCTG-CGG-3 , positions − 66 to − 48); p-54 (5 -gagctcCCTGCG-GGGCGGGGCCTGG-3 ; positions − 54 to − 36); and p-33 (5 -gagctcCAAGCGGCCCGCAG-3 , positions − 33 to − 20) with the reverse primer AACSR; nucleotides in lower-case were added to provide a SacI site at the 5 -end.
Mutant p-97 (M-Inr) was generated from p-97 in which the Inr site was mutated by site-directed mutagenesis by using overlap extension PCR [14] . Briefly, 100 ng of p-97 plasmid was used as a target in two independent PCRs. The first PCR used a forward primer, 5 -gagctcGGGAGGGCGGGGCCTGGAAG-3 , which corresponds to − 97 to − 77 (nucleotides in lower-case were added to provide a SacI site at the 5 -end), and a reverse primer 5 -GCGGCGGCGGGGAACAAGctcgagtACGGCCGCCGCCGC-CTCC-3 , which corresponds to co-ordinates − 20 to + 23. The second PCR used a forward primer, 5 -GGAGGCGGCGGCGGCCGTactcgagCTTGTTCCCCGCCGCCGC-3 , which corresponds to − 20 to + 23, and reverse primer AACSR. The nucleotides in underlined lower-case correspond to those that were changed from the wild-type sequence. In the subsequent overlap extension reaction, 200 ng of each PCR product was used as a target and the primer corresponding to positions − 97 to − 77 and AACSR were used. The PCR product was cloned into the p-GEM-T vector and subsequently subcloned into pGL3 basic, thus generating p-97(M-Inr). Introduction of a TATA box motif into p-33 to construct p-33(TATA) was performed by PCR using the forward primer 5 -gagctcaataattaaCGCAGGAGGCGGCGGCGGCCGTTCAG-3 (nucleotides in lower-case correspond to a SacI site and nucleotides in underlined lower-case correspond to the TATAbox motif) and the reverse primer AACSR.
To verify all constructs, automatic sequencing was performed using the fluorescent terminator kit (PerkinElmer). pSVSport-PPARγ and pJCXRα contained the cDNAs for mouse PPARγ and human RXRα (retinoid X receptor α) respectively, and were provided by Professor B.M. Spiegelman (Harvard Medical School, Boston, MA, U.S.A.) and Dr J.C. Rodríguez (Department of Biochemistry and Molecular Biology, University of Barcelona, Barcelona, Spain) respectively. pRL-CMV (Promega) contained the Renilla luciferase gene under the control of the CMV (cytomegalovirus) intermediate-early enhancer/promoter. pMSV-C/EBPα and pCMV-LIP were kindly provided by Dr M. Giralt (Department of Biochemistry and Molecular Biology, University of Barcelona, Barcelona, Spain). PPARγ -HA (HA is haemagglutinin) was kindly provided by Dr C. Caelles (Institute for Research in Biomedicine, Barcelona, Spain).
Cell culture
All cells were grown at 37
• C and under 5 % CO 2 . Medium was supplemented with 100 units/ml penicillin and 100 mg/ml streptomycin. 3T3-L1 pre-adipocytes were grown in DMEM (Dulbecco's modified Eagle's medium) supplemented with 10 % (v/v) FBS (fetal bovine serum). For adipocyte differentiation, 2-day post-confluent cells (designated day 0) were exposed for 48 h to DMEM supplemented with 10 % (v/v) FBS, 0.5 mM IBMX (isobutylmethylxanthine), 1 mM dexamethasone and 5 mg/ml insulin, followed by a 48-h incubation in DMEM supplemented with 10 % (v/v) FBS and 5 μg/ml insulin [15] . Thereafter, cells were maintained in DMEM supplemented with 10 % (v/v) FBS. Fat accumulation was visualized by staining with Oil Red O (Sigma-Aldrich). The HIB-1B mouse brown pre-adipocyte cell line was cultured in DMEM/F12 (DMEM with Ham's F-12 nutrient mixture) containing 10 % (v/v) FBS as described previously [16] .
Transient transfections
HIB-1B cells were seeded at a density of 0.25 × 10 5 cells/well in 12-well plates 1-day before transfection. Cells were transiently transfected using FuGENE TM -6 reagent, according to the manufacturer's instructions (Roche Diagnostics). For the characterization of the human AACS promoter, HIB-1B cells were transfected with 1 μg of the reporter gene construct and 30 ng of plasmid pRL-CMV (as an internal control). After 48 h cell lysates were collected for the luciferase assay. For the study of the PPARγ -dependent activation of the human AACS gene, HIB-1B cells were co-transfected with 750 ng of the reporter gene construct and, when indicated, with 150 ng of pSVSport-PPARγ and pJCXRα, and 300 ng of pMSV-C/EBPα and/or pCMV-LIP. The plasmid pRL-CMV (30 ng) was included as an internal control and pBluescript KS+ (Stratagene) was used to keep the amount of transfected DNA constant. Cells were incubated for 48 h after transfection and, when indicated, were treated for 24 h before harvest with 10 μM rosiglitazone, 100 nM mithramycin A or vehicle (DMSO or ethanol).
Luciferase assays
The cell extracts were prepared using the passive lysis buffer method (Promega) and firefly and Renilla luciferase activities were determined in a TD-20/20 Luminometer (Turner Designs) using the Dual-Luciferase Reporter Assay System (Promega), according to the manufacturer's instructions.
Animal treatment
All experimental protocols were approved by the Animal Care Research Committee of the University of Barcelona. For in vivo gene expression studies, animals were housed in a temperature-controlled room under a 12 h light/12 h dark cycle and were fed ad libitum. C57/BL6 mice received a gavage with rosiglitazone (30 mg per kg of body weight) or vehicle (1.6 % carboxymethylcellulose), once a day for 10 consecutive days. Thereafter, mice were anaesthetized with isofluorane and adipose tissue (epididymal fat pads) and liver were excised and frozen in liquid nitrogen.
RNA analysis
TRIzol ® reagent (Life Technologies) was used to isolate RNA. Total RNA (1 μg) was reverse transcribed using MMLV (Moloney-murine-leukaemia virus) reverse transcriptase (Invitrogen) and random p(dN)6 primers (Roche Diagnostics) for first strand cDNA synthesis, according to the manufacturer's instructions. The resultant cDNA was subjected to qRT-PCR (quantitative real-time PCR), in which a specific primer and probe mix of mouse AACS (Mm 00513427_m1), PPARγ (Mm 01184322_m1), FABP4 (fatty-acid-binding protein 4, also known as Ap2, Mm 00445878_m1), FAS (fatty acid synthase, Mm 00662319_m1), ACAC (acetyl-CoA carboxylase; Mm 01304257_m1), and ACLY (ATP-citrate lyase; Mm 00652520_m1) were used (Taqman Gene Expression Assay, Applied Biosystems; the reference numbers are the assay ID). Murine differentiation mRNA expression data were normalized to 18S RNA (Applied Biosystems). PCR assays were conducted with the ABI 7700 amplification system (Applied Biosystems).
DAPAs
DAPAs of HIB-1B cells were performed as described previously [17] . Cells were transfected with 10 μg of the HA-tagged PPARγ construct and, when indicated, were treated for 24 h before harvest with 10 μM rosiglitazone. DNA-bound proteins were collected with Tetralink Tetrameric Avidin Resin and separated by SDS/PAGE (8 % gels) and identified by Western blotting. Anti-HA monoclonal antibody (Santa Cruz Biotechnology) was used to detect HA-tagged PPARγ . Sp1 was detected using the PEP2 antibody from Santa Cruz Biotechnology. Biotinylated oligonucleotides comprising the Sp1 sites of AACS (5 -CGGG-AGGGCGGGGCCTGGAAGGGGGCGGGGATTCGAGGCG-GGGCCTGCGGGGCGGGGCCTGGGC-3 ; the consensus Sp1-binding sites are underlined) and the mutated Sp1 sites (5 -CGGGagtctagagcCTGGAAGggtctagagaTTCgatctagagcCTGCggtctagagcCTGGGC-3 : mutated nucleotides are shown in lower-case letters) were synthesized by Sigma-Aldrich.
ChIP assays
ChIP assays were performed as described previously [18] with minor modifications as follows. 3T3-L1 adipocytes on day 6 were treated with 10 μM rosiglitazone for 24 h. In order to cross-link proteins to DNA, adipocytes were treated with formaldehyde to a final concentration of 1 % (v/v) and incubated at 37
• C for 10 min. Cells were washed with PBS and 1 mM PMSF, scraped and collected by centrifugation at 700 g for 4 min at 4
• C. For Sp1 ChIP assays, cells were resuspended in lysis buffer 1 [5 mM Pipes/KOH, pH 8, containing 85 mM KCl, 0.5 % NP-40 (Nonidet P40), 1 mM PMSF and 1 μg/ml of the protease inhibitors leupeptin and aprotinin] and homogenized. Nuclei were isolated by centrifugation at 250 g for 10 min, then resuspended in sonication buffer [50 mM Tris/HCl, pH 8.1, containing 1 % (w/v) SDS and 10 mM EDTA] and sonicated for four cycles of 10 s each using a UP200S sonicator (Dr Hielscher) at cycle 0.5 and an amplitude of 50 %. The extracts were then centrifuged at 10 000 g for 10 min at 4
• C. The cross-linked preparations were diluted 10-fold in ChIP dilution buffer [16.7 mM Tris/HCl, pH 8.1, containing 1 % (v/v) Triton X-100, 1.2 mM EDTA, 167 mM NaCl and protease inhibitors as above]. The chromatin solution was pre-cleared with 80 μl of Protein A-agarose/salmon sperm DNA (Upstate Biotechnology) for 1 h at 4
• C. An aliquot (10 μl) was removed as a control (input). Immunoprecipitation was performed overnight with 20 μg of the anti-Sp1 antibody (Santa Cruz Biotechnology) or pre-immune serum (IgG). Following immunoprecipitation, 60 μl of Protein A-agarose/salmon sperm DNA was added and incubation continued for 4 h. Agarose beads were then collected (centrifugation at 800 g for 2 min) and washed four times for 5 min each time in Sp1 low-salt buffer (20 mM Tris/HCl, pH 8.0, containing 0.1 % Triton X-100, 2 mM EDTA and 150 mM NaCl) and twice with Tris/EDTA buffer (10 mM Tris/HCl and 1 mM EDTA, pH 8.0). For PPARγ ChIP assays, cells were resuspended in lysis buffer 2 [50 mM Tris/HCl, pH 8.1, 1 % (w/v) SDS, 5 mM EDTA 1 mM PMSF and protease inhibitors as above] and, following a 20-min incubation on ice, samples were sonicated with three 15-s pulses as before. The extracts were then centrifuged at 10 000 g for 10 min at 4
• C and the supernatant was collected and diluted 10-fold in ChIP dilution buffer [20 mM Tris/HCl, pH 8.1, 1 % (v/v) Triton X-100, 2 mM EDTA, 150 mM NaCl and the proteases inhibitors as above]. Samples were precleared with 80 μl of Protein A-agarose/salmon sperm DNA for 1 h at 4
• C. An aliquot (10 μl) was removed as a control (input). Immunoprecipitation was performed overnight with 10 μg of the anti-PPARγ antibody or pre-immune serum (IgG). Samples were then incubated with 60 μl of Protein A-agarose/salmon sperm DNA for 1 h followed by 5-min sequential washes in low-salt buffer [ • C for 4 h to reverse the crosslinking. The chromatin-associated proteins were digested with Proteinase K and samples were extracted with phenol/methanol followed by precipitation with ethanol. Pellets were resuspended in water and subjected to PCR. The primers used for amplification were 5 -GAATGAACGAACGAACGAGGG-3 and 5 -CCACAGCGCGAGACTGAAC-3 , located at positions − 264 to − 243 and − 4 to + 15 of the mouse AACS promoter respectively. Primers used for exon 17 amplification were 5 -GAAGCCTTCGATGAGGTGG-3 and 5 -GGAATGCCTCGGGTCTCC-3 . ChIP analysis of PPARγ association with the OLR1 [oxidized low-density lipoprotein (lectin-like) receptor 1] promoter (using the forward primer 5 -TGAACAAACAAGTCGAACCATC-3 and the reverse primer 5 -TGTGGGTGGGGAGAATTATATC-3 , located at positions − 382 to − 361 and − 213 to − 192 respectively) was used as a positive control [19] . Following amplification, the PCR products were electrophoresed in a 2 % (w/v) agarose gel and visualized by staining with ethidium bromide.
-RACE (rapid amplification of cDNA ends)
The 5 -end of the adipose human AACS cDNA was determined using the SMART RACE cDNA Amplification Kit (Clontech). This approach generates full-length cDNAs in reverse transcription reactions [20] . To this end, 1 μg of total RNA from human adipose tissue (Applied Biosystems) was converted into cDNA using PrimeScript TM reverse transcriptase (Takara Bio) following the manufacturer's instructions. 5 -RACE ready cDNA was obtained using the SMART II A and the DH 1114 (5 -CATTCTCTTTGTGCCGCA-3 , positions + 455 to + 472) oligonucleotides. Then a touchdown PCR was conducted with the Universal Primer Mix A from the kit and DH 1115 oligonucleotides (5 -GAGGTTTTCTGCATAGTTGAGC-3 , positions + 433 to + 453), with the Advantage 2 PCR Enzyme System (Clontech). Five initial cycles were carried out (with denaturation at 94
• C for 30 s, annealing at 72
• C for 30 s and extension at 68
• C for 3 min), followed by a further five cycles (with denaturation at 94
• C for 30 s, annealing at 70
• C for 3 min), and a final 27 cycles (with denaturation at 94
• C for 30 s, and 3.5 min of annealing and extension at 68
• C). A nested PCR was performed with the Nested Universal Primer from the kit and DH 782 oligonucleotides (5 -ACCTGGGACCGGAGGAAG-3 , positions + 62 to + 79). Twenty cycles were carried out, with denaturation at 94
• C for 30 s and 3.5 min of annealing and extension at 68
• C. PCR products were resolved in a 1.5 % agarose gel and were then purified and ligated into pGEM-T Easy vector (Promega). Different clones were sequenced using the primer SP6 (5 -GATTTAGGTGACACTATAG-3 ).
Statistical analysis
Statistical differences between experimental groups were determined by a Student's t test using SPSS statistical software. Values of P < 0.05 were considered statistically significant.
RESULTS
The human AACS gene has a TATA-less promoter with an Inr sequence and several GC boxes, which determined its activity BLAST alignment of the genomic sequence of the human AACS gene, containing the 5 -end of the annotated cDNA sequence, with an EST (expressed sequence tag) database showed that there were several ESTs starting 43 nucleotides upstream of the end of the published cDNA [11] . This main position is occupied by an 'A' that is included in a consensus Inr transcription start site (YYANWYY; Figure 1A ). In order to define the transcriptional start site of the AACS gene in adipose tissue, we performed 5 -RACE using a pool of RNAs isolated from human white adipose tissue. We found that there were two main start sites flanking the putative Inr sequence of the AACS gene. We sequenced 36 clones; 19 of these clones started 11 nucleotides upstream of the 'A' in the Inr and 16 of them eight nucleotides downstream of this position.
As expected, the human AACS promoter (from positions − 1425 to + 79 relative to the transcriptional start site) was able to drive luciferase reporter expression, over the promoter-less pGL3basic construct, when transiently transfected in HIB-1B cells ( Figure 1B) .
The analysis of the 5 -region of the AACS gene showed that it is a TATA-less promoter with the described consensus Inr sequence and several GC boxes. To identify the elements that contribute to the core promoter activity, several reporter constructs were analysed, including a scrambling mutation of the Inr and deletion mutants of the GC boxes. Figure 2(A) shows that both the Inr and the GC boxes are needed to promote maximal transcription in HIB-1B cells. Furthermore, the introduction of a recombinant TATA box (30 nucleotides upstream of the transcription start site) does not drive AACS promoter-mediated transcription. To further investigate the role of the putative Sp1-binding sites, several deletion mutants were constructed, eliminating each one of the GC boxes. Figure 2(B) shows that each one of these sequences contributes to the basal activity of the promoter.
The AACS promoter therefore seems to be a focused promoter with a cluster of transcription start sites in a short region of nucleotides; this organization is partially conserved between the rat, mouse and human AACS promoters ( Figure 1C ).
Sp1 bound to the GC boxes of the AACS promoter both in vivo and in vitro
The capacity of Sp1 to interact in vitro with the GC boxes of the human AACS promoter was analysed by pull-down experiments with biotinylated wild-type or mutant probes and HIB-1B cells protein extracts. Figure 3(A) shows the presence of Sp1 in complexes corresponding to the wild-type, but not those corresponding to the mutant probe. The in vivo interaction of Sp1 on the AACS promoter was analysed by ChIP experiments with formaldehyde cross-linked chromatin from 3T3-L1 cells. Figure 3(B) clearly shows the presence of Sp1 proteins bound to the AACS promoter, whereas this interaction was absent in the coding region of the gene (exon 17).
AACS gene expression was induced by PPARγ ligands
We first confirmed previous results showing that AACS mRNA expression was high, particularly in white adipose tissue ( [12] ; results not shown). Furthermore, AACS mRNA increased during adipocyte differentiation [12, 13] . Figure 4 shows that in 3T3-L1 cells, AACS mRNA expression was at its highest level at day six of differentiation and occurred in parallel with the induction of PPARγ expression. To determine whether the expression of the AACS gene was induced in white adipose tissue and liver by PPARγ ligands mice were treated with the PPARγ agonist rosiglitazone. Both in white adipose tissue ( Figure 4B ) and liver ( Figure 4C ) AACS and other PPARγ target lipogenic genes were induced by a similar amount.
PPARγ transcriptionally induced the expression of the human AACS gene
To investigate the effect of PPARγ expression on the transcriptional activity of the AACS gene, a human AACS promoter luciferase reporter construct was transiently co-transfected in HIB-1B cells with or without the expression vectors for PPARγ and RXRα (10 μM rosiglitazone was added when indicated). Figure 5 (A) shows that PPARγ /RXRα expression increased luciferase activity in the presence of rosiglitazone. To identify the regulatory sequences mediating this activation, the experiment was repeated with a series of deletion mutants of the promoter. As shown in Figure 5 (B), the response to PPARγ /RXRα was maintained as long as one of the GC boxes of the AACS promoter was present in the construct.
Adipocyte differentiation is a complex process involving a cascade of expression of many transcription factors, including C/EBP. Recently, C/EBPα [13] has been identified as a transactivator of the mouse AACS promoter, working through a consensus C/EBP-binding site which is not conserved in the human AACS promoter. Also, it has been reported that the transcription factor C/EBP family and Sp1 co-operatively activate a number of genes promoters including CYP2D (cytochrome P450, family 2, subfamily D, polypeptide 6) [21] , human CD11c [22] , lactoferrin [23] , mouse aldose reductase-like gene [24] and mouse IL-10 (interleukin-10) [25] . As shown in Figure 5 (C), the GC-boxcontaining sequence in the proximal human AACS promoter is sufficient for C/EBPα-mediated transactivation, suggesting that the binding of Sp1 to the GC-box-rich sequence is required not just for the basal human AACS gene expression but also for the PPARγ -and C/EBPα-stimulated activity.
Positive co-operativity between PPARγ and C/EBPα has been described [26] . However, the ectopic expression of both C/EBPα with PPARγ /RXR did not increase the AACS-promoter-driven luciferase activity compared with the co-transfection of either C/EBPα or PPARγ /RXR alone (results not shown). In order to discard an indirect effect of PPARγ on the AACS promoter through C/EBPs, the AACS-promoter-driven luciferase reporter was co-transfected with PPARγ and RXRα with or without LIP, which is a dominant-negative form of C/EBPβ. LIP was able to inhibit the activation of the AACS promoter induced by C/EBPα ( Figure 5C ). Figure 5(D) shows that LIP does not prevent the activation of the AACS promoter by PPARγ , but in fact even increases it, suggesting the existence of a functional antagonism between PPARγ and C/EBPα mediated by competition for a critical limiting cofactor. This phenomenon might be explained by the dimerization of LIP with the endogenous C/EBPα, increasing the accessibility of PPARγ to Sp1. However, the mechanistic regulation of the human AACS gene by C/EBPα requires further investigation.
To confirm the importance of Sp1 in the PPARγ -mediated transactivation, we treated the cells with mithramycin, an antibiotic that inhibits the binding of Sp1 to DNA. Figure 5 (E) shows that there was an approx. 50 % reduction in the activity of the AACS promoter by PPARγ in the presence of mithramycin. 
PPARγ was recruited to the AACS promoter by direct interaction with Sp1
An Sp1 and PPARγ interaction has been shown previously [27] and can be reproduced by pull-down experiments with a GST (glutathione transferase)-tagged human PPARγ recombinant protein and Sp1 transcribed and translated in vitro (results not shown). To assess whether the Sp1-binding sites present in the AACS gene recruited PPARγ , we performed DAPAs using HIB-1B cell extracts expressing HA-tagged PPARγ incubated with biotinylated wild-type or GC-mutant probes. Figure 6(A) shows the binding of PPARγ with the wild-type, but not the mutant, probe when the streptavidin-agarose-trapped complexes were analysed via Western blotting with anti-HA-specific antibodies. The interaction of PPARγ with chromatinized DNA was analysed by a ChIP experiment with formaldehyde cross-linked chromatin from differentiated 3T3-L1 cells and a pair of oligonucleotides corresponding to the mouse AACS gene promoter. As shown in Figure 6 (B), the presence of PPARγ was detected in the AACS promoter, whereas this interaction was absent in the coding region of the gene (exon 17). The binding of PPARγ to a known target gene, OLR1 was used as a positive control [19] .
DISCUSSION
Even though the utilization of ketone bodies as a lipogenic substrate in different tissues has been amply documented since the 1970s, their physiological role remains to be elucidated. The AACS gene presents a tissue-specific expression pattern, as it is expressed in several lipogenic tissues. One of the tissues in which the AACS gene is particularly abundant is white adipose tissue. In this tissue, AACS mRNA is preferentially detected in mature adipocytes, but not in pre-adipocytes, and the level increased during adipocyte differentiation [12, 13] . This indicates that AACS contributes to the use of ketone bodies for fatty acid synthesis during adipose tissue development. This is a paradoxical situation, in which ketone bodies produced after the oxidation of fatty acids C57/BL6 mice were gavaged daily with rosiglitazone (30 mg per kg of body weight) or a vehicle for 10 days. At the end of the treatment period, total RNA was isolated from (B) subcutaneous white adipose tissue or (C) liver. Gene expression for individual animals was determined by qRT-PCR assays. **P 0.01; *P 0.05. n = 8 and n = 7 for the white adipose tissue control and treated group respectively; n = 7 or n = 6 for the liver control or treated group respectively. AP2, FABP4.
are used to resynthesize fatty acids in the adipose tissue. This may be an alternative method used to transport fatty acid equivalents across different tissues. Consistent with this putative anabolic role, the expression of the AACS gene is under the control of SREBPs in liver [7] and is decreased in livers from streptozotocin-induced diabetic rats [8, 9] .
We studied the mechanisms controlling the gene expression of human AACS. We isolated the human promoter, characterized the elements required to initiate transcription and analysed the expression of the gene in response to PPARγ , a known master regulator of adipogenesis. The AACS promoter was found to be a TATA-less promoter whose transcriptional activity was driven by an Inr sequence and several GC boxes. Other significant elements present in the core promoters also did not occur in the AACS promoter. The BRE (TFIIB recognition element), an element existing immediately upstream of some TATA boxes, was not present; neither was the DPE (downstream promoter element) typically found in TATA-less promoters. The region between − 3 and + 5 of the AACS promoter contains a consensus Inr site (YYANWYY), which was both sufficient to drive a weak transcription and necessary for the activity of the promoter when the region up to − 93, containing several binding sites for transcription factor Sp1, is added. These results together with those obtained by 5 -RACE from human adipose tissue, suggests that this Inr supports (A) HIB-1B cells were transfected with the HA-PPARγ plasmid and 24 h later, cells were treated with 10 μM rosiglitazone. After a further 24 h, cells were harvested and whole-cell extracts were incubated with biotinylated oligonucleotides containing the Sp1-binding site from human AACS (Wt) or a scrambled sequence of these sites (Mut). WCE, whole cell extracts. Avidin-purified oligonucleotides were processed for Western blot analysis with antibodies against HA. (B) ChIP was performed with antibodies against PPARγ or an unrelated IgG in 3T3-L1 adipocytes. The immunoprecipitates were analysed by PCR using specific primers for the AACS proximal promoter (Sp1-SITE), exon 17 or OLR1. Aliquots of chromatin taken before immunoprecipitation were also analysed (Input).
high levels of transcription, which initiate at a cluster of start sites in a region of several nucleotides. The 5 -flanking region of the human AACS gene also contained several Alu repeats. In the approx. 1.5 kb of the 5 -sequence analysed in the present study there are also two repeats that contains putative response elements for transcription factors [e.g. LXR (liver X receptor) or SREBP], which were potentially involved in regulating AACS gene expression; however, further experimentation revealed that these are non-functional elements (results not shown).
The expression of the AACS gene in adipose tissue, its appearance after PPARγ during differentiation into adipocytes in cell culture and its putative role in adipogenesis, point to this gene being a target for this nuclear receptor. Effectively, our results show that the expression of the AACS gene is induced in cell culture and in mice by treatment with the PPARγ agonist rosiglitazone. To determine whether PPARγ was directly involved in the AACS gene induction, HIB-1B cells were transfected with PPARγ and RXRα expression plasmids and an AACS-promoter-driven luciferase reporter. Subsequently, the transcriptional activity was measured either with or without 10 μM rosiglitazone. These results show that the activity of the reporter can be induced by rosiglitazone and that this induction is augmented in the presence of co-transfected PPARγ and RXRα.
The analysis of the sequence showed the absence of a consensus PPRE (PPAR-responsive element) in the 5 -flanking region of the human AACS gene (at least as far as − 1500 bp relative to the transcription start site). This suggests that a PPRE-independent mechanism might be involved in PPARγ -mediated AACS gene expression. To identify the regulatory sequences that are important for AACS gene induction by PPARγ , we prepared deletion constructs from the human AACS promoter and assayed for PPARγ transactivation. Sequence deletions up to − 54 bp retained the PPARγ -dependent promoter activity. However, deletion of the region between − 54 and − 33 bp resulted in a complete loss of the promoter activity, indicating that this region of the AACS promoter was required for PPARγ -mediated transactivation.
The results of the present study showed the presence of PPARγ on the region of the AACS promoter that contained several GC boxes. Moreover, we showed by DAPA experiments that this interaction occurs through the wild-type GC boxes, as it was not observed when these sequences were mutated. This suggests that induction of AACS by rosiglitazone is dependent on PPARγ interactions, with Sp1 binding to GC boxes sites in the proximal promoter of the AACS gene.
The interaction of PPAR with Sp1 family proteins has been amply documented. For example, a functional interaction of PPAR, RXR and Sp1 in the transcriptional regulation of the acyl-coenzyme-A oxidase promoter has been shown [28] . RNA interference and protein expression/DNA-binding assays suggest that DIM-C-pPhCF 3 [1,1-bis(3 -indolyl)-1-(ptrifluoromethyl)methane] induced p21 expression through a mechanism that involves PPAR interactions with both Sp1 and Sp4 proteins bound to the proximal GC-rich region of the p21 promoter [29] . The hormone-sensitive lipase gene expression is positively regulated by PPARγ and this up-regulation requires the involvement of Sp1 [30] . PPARγ 1 enhances KDR (kinase insert domain receptor) gene expression at the transcriptional level, via the enhancement of binding of Sp1 to the KDR promoter in the absence of its ligands in RCECs (retinal capillary endothelial cells). PPAR ligands, however, suppress KDR gene expression via a decreased interaction between PPAR and Sp1 or Sp3. Hence, PPARγ 1 appears to have bifunctional properties in the regulation of KDR gene expression, mediated via interaction with both Sp1 and Sp3 in RCECs [31] .
However, several studies also show that there PPARγ can have an inhibitory effect of on Sp1 activation. For example, the follistatin promoter is dramatically up-regulated by Sp1, and this regulation was inhibited by PPARγ expression via an interaction with Sp1 that repressed its transcriptional activation function [32] . Activation of PPARγ by its agonists suppresses thromboxane receptor and angiotensin II receptor gene expression in vascular smooth muscle cells by direct interaction of PPARγ with Sp1 [33, 34] . Similarly, in human lung carcinoma cells, PPARγ agonists inhibit fibronectin gene expression, preventing Sp1 from binding to its respective sites [35] . These studies all show that PPARγ can regulate the promoter-specific gene expression by interacting with Sp1.
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